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Small synthetic peptidesoffer greatpotential for vaccines (1, 2). Unfortunately,
such peptides are frequently not immunogenic unless they are given with adju-
vants and linked to carrier proteins (1-3). There is a paucity of safe adjuvants
(1, 4). In addition, peptide-carrier conjugation can be problematic when amino
acids essential to the antigenic determinant are obscured or altered during
conjugation (2). There is alsoconcern that conjugation to routinely used carriers
such as tetanus toxoid may result in epitope suppression ofantipeptide immunity
(5).
We here report a new system that makes synthetic peptides highly immuno-
genic without additional adjuvants by hydrophobically complexing them to
purified preparations of meningococcal outer membrane proteins. These pro-
teins are highly hydrophobic, reflecting their role as transmembrane proteins
and porins (6). Due to their hydrophobic protein-protein interactions, when
appropriately isolated, these proteins form multimolecular structures consisting
of 60-100 nm diameter whole or fragmented membranous vesicles (7). To
emphasize this physical state, we refer to these proteins as proteosomes, since
like liposomes, they are hydrophobic, membranous, multimolecular structures
(although proteosomes prepared as described in this report may vary in size or
shape from those previously pictured [7]). This liposome-like physical state
suggested to us that proteosomesmay notonly begood protein carriers providing
T cell help for peptide immunogenicity, but may also act as adjuvants. Proteo-
somes were also considered potential adjuvants since meningococcal outer mem-
branes (8) and their purified proteins (9, 10) are B cell mitogens in both
conventional and LPS-hyporesponsive C3H/Hej mice (8, 9). The idea that B cell
mitogenicity and adjuvanticity are related is based upon the observation that for
LPS, these functions have a striking positive correlation (11).
Proteosomes have previously beenused to confer immunogenicity upon menin-
gococcal group B polysaccharide when hydrophobically complexed to it and, in
the course of development of this meningococcal vaccine, many people have
been safely immunized with proteosome outer membrane protein complexes
(prepared by other methods [12, 13] or by a protocol similar to that described
in this report (14]). Recently, in fact, proteosomes prepared by the methods used
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here were present in a vaccine that was safely administered to 20,000 individuals
(our unpublished data). Since the ability of group B polysaccharide to complex
and become immunogenic is dependent upon a lipid moiety that is naturally
attached to it (15), we reasoned that any hydrophilic peptide could also complex
to proteosomes and thereby become immunogenic if a hydrophobic foot were
added to one of its ends. While the hydrophobic foot inserted into the proteo-
somes, the hydrophilic peptideepitope could thereby remain both unaltered and
exposed as required. We hypothesized that either a lauroyl group or the penta-
peptide Phe-Leu-Leu-Ala-Val (FLLAV) added to the peptide's NH2 terminus
could serve as the hydrophobic foot.
In this report, we show that peptide vaccines made with proteosomes and
either of these hydrophobic feet induce high levels of specific IgG in both
conventional (BALB/c) and LPS-hyporesponsive (C3H/HeJ) mice without any
additional adjuvants. The peptides we used contain an amino acid sequence
identical to a conserved region of the variable surface glycoprotein (VSG) of
Trypanosoma brucei (16). Inducing immunity to a conserved VSG epitope was
sought because trypanosomes repeatedly change the hypervariable region of
their VSG. Since proteosomes (made by any of several methods described) are
safe for human use (12-14), and since peptide epitopes that are important
antibody binding sites of proteins are generally hydrophilic (17), this novel
system should be applicable to a wide variety ofpeptides that need to be made
into immunogenic vaccines.
Materials and Methods
Peptides.
￿
The peptides used contained the amino acid sequence Tyr-Gly-Gly-Gly-Cys-
Thr-Gln-Ile-Thr-Glu-Pro-Thr-Cys-Asn. This sequence, peptide G, was synthesized alone
and with a hydrophobic pentapeptide (FLLAV) added to its NH2 terminus using the
principles of manual solid-phase synthesis (18). The lauroyl group, CH3(CH),OCO, was
covalently conjugated to the NH2 terminus of peptide G using lauroyl chloride and
pyridine while the peptide was on the resin. The peptides were cyclized by ferricyanide
oxidation to effect disulfide bonding ofthe twocysteines (19). Such cyclic constraints can
be antigenically important by helping maintain a peptide's conformation (20, 21). The
peptides were purified on a C18 silica gel column, eluted as single peaks on reverse-phase
HPLC, and had the expected amino acid analyses. Peptide synthesis, conjugation, and
purification was done by Peninsula Laboratories, Inc., Belmont, CA. The II COOH-
terminal amino acids represented the trypanosome epitope. Tyrosine was added for '251
tracing and two glycines were added as spacers.
Proteosomes.
￿
Outer membrane complex vesicles were extracted from group B serotype
2b meningococci as described (12), and outer membrane proteins were isolated from the
other components by solubilization in a buffer with 1% zwitterionic detergent, Empigen
BB (Albright and Wilson, Whitehaven, Cumbria), followed by precipitation with
(NH4)2SO4 three times (500 g/liter) and dialysis against 0.1% Empigen BB buffer as
described (14). PAGE in SDS showed three major protein bands with molecular weights
of43, 41, and 28 x 10'. There was <1% LPS, polysaccharide, and nucleic acid.
Complexing the Peptides to the Proteosomes.
￿
Hydrophobic binding ofthe peptides (with
either the lauroyl or the pentapeptide hydrophobic foot) to the proteosomes wasdone by
resuspending equal amounts (by weight) ofeach ofthe components in a 1% solution of
Empigen BB, buffered to pH 8.5 with Tris, EDTA, and NaCl. The components were
combined to yield a final concentration of 1 mg/ml of each of the components and the
mixture was exhaustively dialled across a 1,000 mol wt cutoff membrane against PBS,
pH 8.5, for 8-10 d. Using '2 I-labeled peptide it was found that ^-75% of peptide was660
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FIGURE 1.
￿
Immunogenicity of peptide G complexed to proteosomes via either the lauroyl
or FLLAV hydrophobic foot. (a-d) BALB/c mice; (e and f) C3H/HeJ mice; (a, c, and e)
peptide G complexed to proteosomes via the lauroyl foot; (b, d, andf) peptide G complexed
to proteosomes via the FLLAV pentapeptide foot; (a, b, e, andf) IgG responses; (c and d) IgM
responses; (0) primary response; (A) secondary response; (x) tertiary response; (EI) 6-mo
response; (*) control groups, all responses; the control groups received peptide G in either
saline or CFA or mixed with proteosomes; or peptide G linked to either the lauroyl or FLLAV
hydrophobic foot without proteosomes.
retained after dialysis. Gel filtration over a Sephadex G-200 column indicated that >90%
of the peptide eluted with the proteosomes in the void volume. The peptide/protein
molar ratio in the vaccines was 16:1 . If as is thought, 20-40 protein molecules constitute
each multimolecular proteosome, they may bind as many as 300-600 peptide molecules
each.
Immunization.
￿
Groups of five to eight mice were immunized intraperitoneally with
vaccines containing 40 kg of peptide and boosted with the same vaccines 3 and 7 wk later.
No adjuvants were given except, as noted, in control groups. Sera were collected 2-3 wk
after each immunization and tested in an ELISA using a microplate reader (Dynatech
Laboratories, Inc., Alexandria, VA) as previously described (22). The secondary antibody
was affinity-purified alkaline phosphatase-conjugated goat anti-mouse IgG or IgM. The
detecting antigen in the ELISA was peptide G used either alone (at 2 Ag/ml and allowed
to dry overnight) or linked to BSA. Since results were similar with both antigens but more
consistent with the coupled peptide, this antigen was used routinely. Testcontrols ensuring
specificity included using a heterologous peptide (alone or linked to BSA) or BSA alone
as detecting antigens.
Results and Discussion
Immunization of BALB/c mice with peptide G hydrophobically complexed to
proteosomes via either the lauroyl (Fig. 1 a) or FLLAV (Fig. I b) hydrophobic
foot resulted in exceedingly high serum anti-peptide G IgG titers after two or
three immunizations. IgM titers were much lower (Fig. 1, c and d). None of the
control vaccines (see legend) induced significant antibodies. The anamnestic IgG
responses indicate that proteosomes complexed to peptides hydrophobically do
provide protein carrier T cell help.E
un O V
w
z a
s 0
2 .0
c 0 .5
0
LOWELL ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
661
HETEROLOGOUS PEPTIDE
HOMOLOGOUS PEPTIDE
.0
1
￿
I
￿
I
0 0.7 1.5 3 .1 6 .25 12.5
FIGURE 2.
￿
Inhibition of antibody binding by homolo-
gous but not heterologous antigens. Before use in the
ELISA, sera were preincubated for I hat 4°Cwith either
peptideG(devoidofhydrophobic feet)or a heterologous
peptide linked to BSA.
uglmlPEPTIDE PRE-INCUBATED WITH SERA
The proteosome vaccines with the lauroyl foot (Fig. 1 e) and the FLLAV
pentapeptide foot (Fig. If) were also highly immunogenic in C3H/HeJ mice,
which are hyporesponsive to the adjuvant effects of LPS (11). The effect of the
proteosomes was therefore not due to the <1% LPS in the proteosome prepa-
rations.
In both BALB/c and C3H/HeJ mice, anti-peptide G IgG titers were high
even 6 mo after immunization (Fig. 1, a, b, e, andf). The proteosome vaccines
also induced high anti-meningococcal protein IgG in both mouse strains (data
not shown).
Antibody binding to peptide G was specifically inhibited by homologous but
not heterologous peptides; hence, the antibodies induced were specific for the
immunizing peptide (Fig. 2). Notwithstanding this specificity, conserved trypan-
osome VSG epitopes may not be as useful as had been hoped since this part of
the VSG of live trypanosomes appears to be unavailable to antibodies (23).
Indeed, in fluorescent assays, monoclonal and polyclonal antibodies to several
conserved VSG epitopes (including peptide G) bound to acetone-fixed but not
to live trypanosomes (Hall, T., personal communication).
Dreesman et al. (21) reported that an uncoupled cyclic peptide given with
CFA or alum induced antibodies detectable in 50% of murine sera diluted 1 :4.
Hopp (24) andJacob et al. (25) enhanced peptideimmunogenicity by immunizing
with CFA emulsions of peptides conjugated to the hydrophobic moiety dipalmi-
toyl-lysine. In contrast, our proteosome-hydrophobic foot peptide vaccines in-
duced high IgG titers without any adjuvant. Furthermore, without proteosomes,
our cyclic peptide was not immunogenic, even when hydrophobic feet were
added or when CFA was used.
These data suggest that proteosomes may serve as an adjuvant as well as a
protein carrier. Such adjuvanticity may be related to proteosomes' B cell mito-
genicity (9-11). A relationship between adjuvanticity and mitogenicity has been
demonstrated for LPS (11) and for a tripalmitoyl-peptide analogue of Escherichia
coli lipoprotein (26). Unlike LPS, proteosomes are effective in C3H/HeJ mice in
vitro (8, 9) and in vivo (Fig. 1, e andf). B cell mitogens may act as adjuvants by
expanding B cell clones or by providing a second signal to stimulate antibody
production. Alternatively, peptides complexed to Bcell mitogens maybe targeted
to Bcellswhen thesecellsbind themitogen viatheirmitogen receptors. Enhanced662
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immunogenicity wouldoccur ifthese B cells could then, as APCs, more efficiently
present the mitogen-bound peptides to helper T cells. In this regard, it has
recently been shown (27) that complexing an antigen to anti-immunoglobulin
can increase immunogenicity and B cell antigen processing by targeting the
antigen to B cell surface immunoglobulin antigen receptors (27).
Summary
Addition of either a lauroyl or a pentapeptide (FLLAV) hydrophobic foot to
the NH2 terminus of a small, synthetic peptide allowed the peptide to hydro-
phobically complex to meningococcal outer membrane protein proteosomes by
simple dialysis. Both conventional and LPS-hyporesponsive mice immunized with
these complexes without any adjuvants developed high-titered and persistent
anti-peptide IgG. Since proteosomes have been safely given to many people and
since important antigenic determinants are generally hydrophilic, this system
should be widely applicable to the development of peptide vaccines for human
use.
We gratefully acknowledge Dr. Eli Schmell for his helpful discussions of biochemical
techniques and Dr. Theodore Hall for providing background information about trypan-
osome VSG peptides.
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